Adam Giermasz

Co-Director, Hemophilia Treatment Center
University of California Davis Medical Center

Presentation(s):

• VPB1189 - ATHN 16: Safety of Coagulation Factor VIIa (recombinant)-jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia A or B with Inhibitors, with or without Prophylactic Treatment

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM